RxSight stock target cut to 6 US dollars by Wells Fargo

Published on 11/06/2026 at 00:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wells Fargo cut its RxSight stock target after a weak third quarter. Management is expanding its US sales force and targeting lower costs in 2027.

RxSight faces earnings pressure

Wells Fargo cut its RxSight price target to 6 US dollars from 9 US dollars while retaining an Equal Weight rating.
Third-quarter revenue fell 19 percent year over year as competition, seasonality and restructuring disruption weighed on demand.
Management expects fourth-quarter LAL sales to be in line with the second quarter and plans lower operating expenses in 2027.

RXST, US78349D1072, Illustration mit AI erstellt.

Wells Fargo cut its price target for RxSight stock to 6 US dollars from 9 US dollars on Wednesday, November 4, while keeping an Equal Weight rating. The analyst move followed RxSight's third-quarter results, which showed weaker revenue and continued competitive pressure.

According to Markets Insider, Wells Fargo cited seasonality, competitive product trials and disruption from restructuring. The firm expects fourth-quarter Light Adjustable Lens sales to be in line with the second quarter and lower operating expenses in 2027.

Third-quarter pressure persists

RxSight reported third-quarter revenue of 24.6 million US dollars for the period ended September 30, 2026, down 19 percent from a year earlier. Light Adjustable Lens procedure volume fell 11 percent to 23,128 units, while the company posted a net loss of 16.2 million US dollars, or 0.39 US dollars per share.

The company has suspended formal 2026 guidance and plans to resume guidance with its fourth-quarter results. Management is nearly doubling its US sales force and expects restructuring actions across manufacturing, corporate functions and international operations to reduce expenses from 2027 onward.

RxSight's business and competitors

RxSight is a commercial-stage medical technology company based in Aliso Viejo, California, focused on improving vision after cataract surgery. Its FDA-approved system combines the Light Adjustable Lens and Light Delivery Device, allowing doctors to refine lens power after surgery. The company primarily serves the US ophthalmic market and remains a specialized participant in premium intraocular lenses, competing with larger suppliers including Alcon, Johnson & Johnson and Bausch + Lomb.